Prognostic factors in non-small cell lung cancer.

Identification of prognostic factors is critical in optimizing treatment for patients with cancer. The purpose of this work is to review the modern literature with regard to prognostic factors for patients with non-small-cell lung cancer (NSCLC) taking into account ongoing advances in clinical evaluation, staging, surgery, radiation therapy, chemotherapy, and molecular biology in this widely heterogeneous patient population.

[1]  E. Gore,et al.  Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. , 2002, International journal of radiation oncology, biology, physics.

[2]  T. Okamoto,et al.  Problems related to TNM staging: patients with stage III non-small cell lung cancer. , 2002, The Journal of thoracic and cardiovascular surgery.

[3]  B. Jeremic,et al.  Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[4]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[5]  S. Sak,et al.  Prognostic implications of microscopic proximal bronchial extension in non-small cell lung cancer. , 2002, The Annals of thoracic surgery.

[6]  M. Paci,et al.  Controversies over UICC-TNM classification of non-small cell lung cancer: model for a diagnostic path. , 2002, Chest.

[7]  R. Clough,et al.  Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[8]  M. Bousamra,et al.  Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[9]  Sen Zhao,et al.  Prognostic Factors for Local Control in Non–Small-Cell Lung Cancer Treated With Definitive Radiation Therapy , 2002, American journal of clinical oncology.

[10]  Kurt Baier,et al.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[11]  D. Ball,et al.  Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. , 2001, International journal of radiation oncology, biology, physics.

[12]  M Werner-Wasik,et al.  Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. , 2001, International journal of radiation oncology, biology, physics.

[13]  M. Riquet,et al.  Surgical management of non-small cell lung cancer with synchronous brain metastases. , 2001, Chest.

[14]  W. Sause.  Nonsurgical management of non-small-cell lung cancer. , 2001, Hematology/oncology clinics of North America.

[15]  A. Bernard,et al.  Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. , 2001, The Annals of thoracic surgery.

[16]  W. Richards,et al.  Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. , 2000, The Annals of thoracic surgery.

[17]  W. Sause,et al.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. , 2000, International journal of radiation oncology, biology, physics.

[18]  N Cheynel,et al.  Identification of prognostic factors determining risk groups for lung resection. , 2000, The Annals of thoracic surgery.

[19]  J. Manola,et al.  Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (Tx): Implications of ECOG 5592 , 2000 .

[20]  D. Grunenwald.  Surgery for advanced stage lung cancer. , 2000, Seminars in surgical oncology.

[21]  S. Hahn,et al.  Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. , 1999, Radiology.

[22]  Kenji Suzuki,et al.  Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma , 1999, Cancer.

[23]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  M. Okada,et al.  Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. , 1999, The Annals of thoracic surgery.

[25]  R. Komaki,et al.  Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience. , 1999, International journal of radiation oncology, biology, physics.

[26]  H. Li,et al.  Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: implications in the inoperable and three-dimensional dose-escalation settings. , 1999, International journal of radiation oncology, biology, physics.

[27]  H. Asamura,et al.  Implications of staging in lung cancer. , 1997, Chest.

[28]  T. Wigren.  Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  T. Pajak,et al.  Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. , 1997, Lung cancer.

[30]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[31]  N. Choi,et al.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Chevret,et al.  Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma: Correlation with TNM stage and disease free and overall survival , 1996, Cancer.

[33]  A. Chella,et al.  Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA‐N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence , 1996, Cancer.

[34]  S. Cha,et al.  Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma , 1996, Cancer.

[35]  B. Jeremic,et al.  Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. , 1995, Lung cancer.

[36]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Gebski,et al.  Radical radiotherapy for early nonsmall cell lung cancer. , 1995, International journal of radiation oncology, biology, physics.

[38]  C. Angeletti,et al.  Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. , 1993, The Journal of thoracic and cardiovascular surgery.

[39]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Curran,et al.  Comparison of the radiation therapy oncology group and american joint committee on cancer staging systems among patients with non‐small cell lung cancer receiving hyperfractionated radiation therapy. A report of the radiation therapy oncology group protocol 83‐11 , 1991, Cancer.

[41]  A R Feinstein,et al.  A Clinical‐Severity Staging System for Patients with Lung Cancer , 1990, Medicine.

[42]  R. Peschel,et al.  Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. , 1987, International journal of radiation oncology, biology, physics.

[43]  D. Page,et al.  Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population , 1987, Journal of surgical oncology.

[44]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[45]  Z. Petrovich,et al.  Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung , 1979, Cancer.

[46]  B. Linn,et al.  CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.

[47]  H. Oksanen,et al.  A practical prognostic index for inoperable non-small-cell lung cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[48]  Jeffrey D Bradley,et al.  Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[49]  N Zamboglou,et al.  Predictive factors in radiotherapy for non-small cell lung cancer: present status. , 2001, Lung cancer.

[50]  M. Green,et al.  The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? , 1999, Chest.

[51]  W. Sause,et al.  The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. , 1999, International journal of radiation oncology, biology, physics.

[52]  W. Curran,et al.  Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone. , 1992, International journal of radiation oncology, biology, physics.

[53]  P. Blitzer,et al.  Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. , 1992, International journal of radiation oncology, biology, physics.

[54]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.